BioStock Values SynAct’s Resomelagon Across Three Indications at SEK 2.9B
BioStock’s BioVal analysis estimates a combined value of SEK 2.9 billion across three indications for SynAct’s resomelagon.
BioStock’s BioVal analysis estimates a combined value of SEK 2.9 billion across three indications for SynAct’s resomelagon.